Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135609 | 0.76 | KDM1A (0.63) | KDM1AMAOBMAOASMN1; SMN2NPSR1 | |
| SCHEMBL25069642 | 0.76 | KDM1A (0.63) | KDM1AMAOBMAOASMN1; SMN2NPSR1 | |
| SCHEMBL4135605 | 0.76 | KDM1A (0.63) | KDM1AMAOBMAOASMN1; SMN2NPSR1 | |
| SCHEMBL12870250 | 0.76 | KDM1A (0.63) | KDM1AMAOBMAOASMN1; SMN2NPSR1 | |
| SCHEMBL2756020 | 0.70 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL15130495 | 0.70 | KDM1A (0.52) | KDM1AMAOBMAOA | |
| SCHEMBL239559 | 0.70 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL239558 | 0.70 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL553460 | 0.69 | — | — | |
| SCHEMBL20420603 | 0.69 | KDM1A (0.77) | KDM1AMAOBMAOASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045456-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2016-02-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045456-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KDM1A 1515/4885MAOB 143/4885MAOA 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.